NuPathe, which is developing Zelrix, a migraine treatment that recently completed Phase 3 trials and expects to launch in 2012, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Conshohocken, PA-based company, which was founded in 2005 and has yet to generate product revenue, plans to list on the NASDAQ under the symbol PATH. Leerink Swann and Lazard Capital Markets are the lead underwriters on the deal. Pricing terms and timing were not disclosed by NuPathe, which is the 10th company to file for an IPO so far this week.
